Search hospitals > Ohio > Dayton
First Dayton Cancer Care
Claim this profileDayton, Ohio 45420
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
181 reported clinical trials
1 medical researcher
Summary
First Dayton Cancer Care is a medical facility located in Dayton, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. First Dayton Cancer Care is involved with conducting 181 clinical trials across 294 conditions. There are 1 research doctors associated with this hospital, such as Howard M. Gross.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Clinical Trials running at First Dayton Cancer Care
Non-Small Cell Lung Cancer
Bladder Cancer
Breast Cancer
Bladder Carcinoma
Lung Cancer
Cancer
Renal Cell Carcinoma
Squamous Cell Carcinoma
Gastric Cancer
Esophageal Adenocarcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at First Dayton Cancer Care?
First Dayton Cancer Care is a medical facility located in Dayton, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. First Dayton Cancer Care is involved with conducting 181 clinical trials across 294 conditions. There are 1 research doctors associated with this hospital, such as Howard M. Gross.